Telmisartan prevents cardiovascular events in a broad group of at-risk patients

Author： Baumhäkel Magnus   Böhm Michael  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.18, 2009-12, pp. : 3113-3117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ramipril cost effective in patients at high risk for cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Ramipril cost effective in patients at high risk for cardiovascular events

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 464, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Ephedra: risk of adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Ranolazine dose not reduce the risk of major cardiovascular events in patients with acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1586, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Non-compliance and discontinuation increases the risk of cardiovascular events in patients receiving low-dose aspirin

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 11, 2010-11 ,pp. : 24-26

Adis International

Access to resources Recommend Favorite